QPCR (quantitative polymerase chain reaction)-based peripheral blood free DNA (deoxyribonucleic acid) polygene methylation detection system
Through the peripheral blood free DNA multi-root methylation detection system based on qPCR, combined with immunoprecipitation method and fluorescence quantitative PCR technology, the problem of detection of multiple cancer types in the existing technology is solved, and high-efficiency and low-cost methyl is achieved. Metastatic signal detection meets the needs of early cancer screening.
Patent Information
- Application Number
- CN202411432859.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-15
- Publication Date
- 2024-11-26
AI Technical Summary
The existing peripheral blood free DNA multigene methylation detection technology cannot meet the simultaneous detection needs of multiple cancer species, and is costly. The traditional disulfite treatment method has low sensitivity to single detection and cannot effectively meet early cancer screening. Check the clinical needs.
Using a peripheral blood free DNA multigene methylation detection system based on qPCR, the cfDNA extraction unit and methylation enrichment purification unit are combined with immunoprecipitation method and fluorescence quantitative PCR technology to achieve efficient detection of multiple target genes and reduce the Signal loss during extraction and processing is achieved, and the sensitivity of methylated signals is improved.
Simultaneous detection of multiple cancer species is achieved, the sensitivity and sensitivity of methylated signals is improved, the detection cost is reduced, the clinical needs of early cancer screening is met, and the high cost of high throughput sequencing is avoided.
Smart Images

Figure CN119020462A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the fields of molecular biology and gene detection, and more specifically, to a peripheral blood free DNA multi-gene methylation detection system based on qPCR. Background Art
[0002] In recent years, liquid biopsy technology based on molecular diagnostic technologies such as PCR and NGS, which uses non-solid biological tissues as specimens for sampling, has developed rapidly and has broad application prospects in many fields such as early cancer screening. Liquid biopsy is a non-invasive blood test that can determine the genetic mutation of a tumor by detecting circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) fragments and exosomes released into the blood by tumors or their metastases.
[0003] Abnormal ctDNA methylation in peripheral blood free DNA is considered to be one of the important epigenetic modifications that drive the development of cancer, and it often occurs early in the course of cancer. ctDNA methylation is one of the most mature features used in early cancer screening.
[0004] At present, most screening methods can only screen for specific cancer types and cannot meet the needs of users who want to complete screening for multiple cancer types in one test. There is no mature multi-cancer joint detection technology in China for pan-cancer detection, and the detection performance of pan-cancer early screening has not yet met clinical needs. At the same time, due to the widespread use of high-throughput methylation sequencing technology or multi-omics sequencing technology, the development and detection costs of multi-cancer systems are very high.
[0005] DNA methylation detection methods include bisulfite conversion sequencing (BS-Seq), MeDIP-Seq, RRBS-Seq, WGBS, MBD-Seq, SMRT, etc. Among them, Whole Genome Bisulfite Sequencing (WGBS) is regarded as the "gold standard" for DNA methylation research. It uses bisulfite to treat DNA to cause unmethylated C to become U and become T in the subsequent PCR and sequencing process, while methylated C is not affected by bisulfite. The subsequent sequencing of the treated genomic DNA library can analyze the methylation status of the entire genome. It has a single-base resolution and can accurately evaluate the methylation level of a single C base. It has a wide coverage, but the cost is high.
[0006] The qPCR detection platform based on the bisulfite treatment method, taking the blood Septin9 methylation detection as an example, its main limitation is that the recognition sensitivity of colorectal cancer and precancerous lesions (adenomas) is relatively low, and the sensitivity of advanced adenomas is only 7.9% to 38.7%. Increasing the number of methylated genes can improve the sensitivity of colorectal cancer, but it still cannot meet the actual clinical needs. Since the blood collection volume of a single blood specimen in clinical practice is generally in the range of 3mL to 20mL, the qPCR technology based on the existing bisulfite methylation analysis can only achieve a limited number (generally no more than 10) of methylated genes for a single ctDNA sample. The product with the most genes for a single test that has been approved by the National Medical Products Administration is the human Septin9, BCAT1, IKZF1, BCAN, and VAV3 gene methylation combined detection reagent, which extracts free DNA from 3mL of plasma and detects 6 methylated regions of 5 genes. However, it can only meet the detection of one type of cancer, and cannot meet the detection of multiple types of cancer and multiple genes.
[0007] Therefore, when the amount of blood collected is limited, how to avoid excessive loss of trace early molecular signals, improve the extraction and purification efficiency of target nucleic acids in peripheral blood free DNA samples, and at the same time achieve sensitive detection of multiple cancer-specific gene methylation markers at low cost, is an urgent problem that needs to be solved in the early screening of cancer and early diagnosis of chronic diseases. Summary of the invention
[0008] In a first aspect of the present invention, a qPCR-based peripheral blood free DNA multi-gene methylation detection system is provided, comprising:
[0009] 1) cfDNA extraction unit: used to extract cfDNA from plasma samples. When the double-stranded DNA yield of the extracted cfDNA product is not less than 0.5 ng per mL of plasma, it enters the cfDNA methylation enrichment and purification unit:
[0010] 2) cfDNA methylation enrichment and purification unit: used to pre-amplify cfDNA and enrich and purify methylated DNA using immunoprecipitation to obtain an indiscriminately amplified methylated DNA enriched library;
[0011] When the recovery rate of the methylated quality control product is not less than 65% and the recovery rate of the non-methylated quality control product is not higher than 1%, enter the qPCR amplification unit;
[0012] 3) qPCR detection unit: used to detect methylated DNA and obtain qPCR detection results.
[0013] Preferably, in the cfDNA extraction unit, the method for extracting cfDNA from a plasma sample comprises the following steps:
[0014] S11. Place 2 mL of plasma into a centrifuge tube containing 100 μL to 150 μL of proteinase K, add 100 μL to 150 μL of lysis solution 1, mix well, and react at 15-60° C. for 10-60 minutes to obtain a mixed solution;
[0015] S12. Add 4 mL to 8 mL of lysate 2 and 30 μL to 50 μL of magnetic beads to the mixed solution obtained in S11, mix well at room temperature, and react for 10 to 60 minutes; transfer to a magnetic rack after centrifugation, adsorb the magnetic beads, and discard the solution;
[0016] S13. Add 0.5 mL to 0.8 mL of washing solution 1, mix well, centrifuge, place on a magnetic stand for adsorption, and discard the solution;
[0017] S14. Add 0.5 mL to 0.8 mL of washing solution 2, mix well, transfer to a magnetic stand for adsorption, and discard the solution;
[0018] S15. After centrifugation, remove all residual liquid; dry the magnetic beads in air for 2 to 5 minutes;
[0019] S16. Add 50 μL to 100 μL of elution buffer 1, dissolve the DNA and transfer it to a magnetic rack for adsorption. Transfer the supernatant containing cfDNA to a new centrifuge tube to obtain the cfDNA extraction product.
[0020] Preferably, the lysis solution 1 comprises 0.05% to 1% sodium citrate dodecahydrate and 1% to 5% SDS;
[0021] Lysis solution 2 contains 10% to 20% guanidine thiocyanate, 1% to 5% NP40, 3% potassium chloride, 2% sodium chloride, 0.1% to 0.3% sodium dihydrogen phosphate, 0.5% to 1% tris(hydroxymethyl)aminomethane, 0.05% to 0.2% sodium tartrate and 25% isopropanol;
[0022] The washing solution 1 comprises 20% to 25% guanidine thiocyanate, 0.2% to 1% SDS, and 30% to 50% anhydrous ethanol;
[0023] Washing liquid 2 contains 0.1% to 0.8% tris(hydroxymethyl)aminomethane, 0.5% to 1% TrintonX-100, and 70% to 80% anhydrous ethanol;
[0024] The eluent 1 contains 0.05% to 0.2% of tris(hydroxymethyl)aminomethane.
[0025] More preferably, the components of lysate 1 are 0.07% sodium citrate dodecahydrate and 4% SDS;
[0026] Lysis solution 2 consists of 20% guanidine thiocyanate, 3% NP40, 3% potassium chloride, 2% sodium chloride, 4% sodium lauroyl amino acid, 0.1% sodium dihydrogen phosphate, 0.7% tris(hydroxymethyl)aminomethane, 0.05% sodium tartrate and 25% isopropanol;
[0027] The washing liquid 1 further contains 0.2% to 0.5% of tris(hydroxymethyl)aminomethane and 1.5% to 5% of potassium chloride.
[0028] Preferably, in the cfDNA extraction unit, the magnetic beads are amino-siliconized magnetic beads.
[0029] Preferably, in the cfDNA methylation enrichment and purification unit, the method for enriching methylated fragments in human peripheral blood free DNA comprises the following steps:
[0030] S21. adding λDNA as a DNA methylation protective agent to the sample to be tested to obtain a sample to which λDNA is added;
[0031] S22. Mix the immunoprecipitation buffer and the sample with added λDNA, incubate at 90-95°C for 5-20 minutes, and then cool rapidly to obtain a mixed solution;
[0032] S23. Add the antibody and magnetic beads to the mixture obtained in step S2 and incubate at 2-8°C for 4-16 hours;
[0033] S24. After instant centrifugation, place on a pre-cooled magnetic rack and discard the supernatant; wash the magnetic beads with washing solution;
[0034] S25. Elute the DNA with elution buffer at 50-60℃ / 15min, 95-100℃ / 15min.
[0035] Preferably, in step S21, in the DNA methylation protecting agent, the mass ratio of methylated λDNA to unmethylated λDNA is 1:1.
[0036] Preferably, in the sample to which λDNA is added, the mass ratio of cfDNA to DNA methylation protectant is 1:10-1:40, wherein the concentration of cfDNA is not less than 0.01 ng / μL.
[0037] Preferably, in step S22, during mixing, the volume ratio of the immunoprecipitation buffer and the sample to which λDNA is added is (30-35) μL:(55-60) μL.
[0038] Preferably, in step S22, the immunoprecipitation buffer comprises 0.1-0.2 M sodium phosphate solution, 1-2 M sodium chloride solution, and 1%-5% Triton X-100.
[0039] Preferably, step S23 further includes a step of washing the magnetic beads and a step of diluting the antibody:
[0040] Washing step of magnetic beads: take 2-6 μL of 10 mg / mL magnetic bead stock solution and wash the magnetic beads with ten-fold diluted immunoprecipitation buffer, wash at least twice, and resuspend with 20 μL of ten-fold diluted immunoprecipitation buffer for the last time to obtain a magnetic bead suspension with a concentration of 1-3 mg / mL;
[0041] Antibody dilution step: Dilute the 5-methylcytosine antibody at a concentration of 1 mg / mL by 10-100 times using ten-fold diluted immunoprecipitation buffer to obtain a solution with an antibody concentration of 0.01-0.1 mg / mL.
[0042] Preferably, in step S23, the antibody, magnetic beads, and the mixed solution obtained in step S22 are mixed in the following volume ratio: 1:1:(15-20).
[0043] Preferably, in the cfDNA methylation enrichment and purification unit, the magnetic beads are IgG magnetic beads.
[0044] Preferably, in the cfDNA methylation enrichment and purification unit, the antibody is a 5-methylcytosine antibody.
[0045] Preferably, in step S24, the washing solution comprises a ten-fold diluted immunoprecipitation buffer and an immunoprecipitation buffer with a high sodium chloride salt concentration; the immunoprecipitation buffer with a high sodium chloride salt concentration comprises 0.01-0.02M sodium phosphate solution, 1-4M sodium chloride solution, and 0.1%-0.5% Triton X-100.
[0046] Preferably, in step S25, the eluent 2 comprises 0.01-0.1 M Tris-HCl, 0.01-0.1 M EDTA, 0.001-0.1% SDS, and 0.1-1 mg / mL proteinase K.
[0047] Preferably, in the qPCR detection unit, primers and probes are designed for the target-specific differential methylation region, and the differential methylation region covers no less than 4 CpG sites.
[0048] Preferably, in the qPCR detection unit, the qPCR reaction uses TSH2B as an internal reference gene, and the chromosome location is: chr6:25726855-25727020.
[0049] Preferably, the internal reference gene also includes GAPDH, and the chromosome position of Hg38 coordinates is: chr12: 6534476-6534539.
[0050] Preferably, the peripheral blood free DNA multi-gene methylation detection system based on qPCR also includes:
[0051] 4) Algorithm analysis unit: used to analyze the qPCR test results, including: calculating ΔCT by subtracting the CT value of the reference gene from the CT value of the target gene; calculating the logistic score of each sample by a logistic regression model (LogisticRegression) based on the ΔCT value of a single gene or multiple genes, selecting an appropriate cut-off value (cut-off value) according to different logistic scores, and judging the sample as positive when the score is higher than the cut-off value, and judging the sample as negative when the score is lower than the cut-off value.
[0052] The second aspect of the present invention provides a kit for extracting and enriching methylated fragments in free DNA in human peripheral blood, comprising: the above-mentioned lysate 1, lysate 2, washing solution 1, washing solution 2 and eluent 1, as well as the above-mentioned immunoprecipitation buffer, a ten-fold diluted immunoprecipitation buffer with a high sodium chloride salt concentration, and eluent 2.
[0053] The third aspect of the present invention provides the above-mentioned qPCR-based peripheral blood free DNA multi-gene methylation detection system, a method for extracting cfDNA in a plasma sample in the system, a method for enriching methylated fragments in human peripheral blood free DNA in the system, and the above-mentioned lysate 1, lysate 2, washing solution 1, washing solution 2 and eluent 1, as well as the above-mentioned ten-fold diluted immunoprecipitation buffer, immunoprecipitation buffer, ten-fold diluted immunoprecipitation buffer with high sodium chloride salt concentration and eluent 2 in the detection, screening and assessment of disease risks of DNA methylation levels.
[0054] The present invention uses a mild nucleic acid treatment technology - non-bisulfite treatment technology - methylated DNA immunoprecipitation enrichment (MeDIP) to establish a peripheral blood free DNA super multi-gene methylation qPCR detection system. This system is limited to meet the conditions of peripheral blood free DNA nucleic acid extraction efficiency and reduce the occurrence of large fragment contamination during the extraction process, and further use immunoprecipitation technology to improve the enrichment and purification effect of methylated target nucleic acids. Through the indiscriminate amplification of methylated target signals, the fluorescent quantitative PCR technology can simultaneously realize the synchronous detection of super-multiple target genes.
[0055] The system has good openness and can expand the number of detected genes according to actual needs. It can meet the needs of conducting joint detection of multiple target genes at the same time to obtain indicators of multiple cancer types and multiple types of diseases.
[0056] Compared with traditional bisulfite treatment, efficient cfDNA extraction and methylation enrichment and purification technology avoids excessive loss of trace signals and protects the integrity of early tumorigenesis signals, making it a more preferred option for methylation analysis. It greatly reduces damage to peripheral blood free DNA, improves the sensitivity of methylation signals, and enhances the sensitivity of target gene detection.
[0057] The technology system based on fluorescent quantitative PCR avoids the high cost of high-throughput sequencing platforms, is simple to operate, and has extremely high clinical popularity. It can provide valuable methylation basis for early screening of single or multiple tumors, early diagnosis of single or multiple diseases, and the development of chronic diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1 A flow chart of the system is shown.
[0059] Figure 2 The difference in area under the main peak of cfDNA fragment distribution detected by capillary electrophoresis in Test Example 1 is shown.
[0060] Figure 3 The difference in the main peak position of cfDNA fragment distribution detected by capillary electrophoresis in Test Example 1 is shown.
[0061] Figure 4 The capillary electrophoresis detection of cfDNA fragment distribution and the difference in large fragment interference peaks in Test Example 1 are shown.
[0062] Figure 5 The comparison results of the binding efficiency of methylated genes (meDNA) and unmethylated genes (unDNA) in Test Example 2 are shown.
[0063] Figure 6 The experimental flow of Test Example 3 is shown.
[0064] Figure 7 The evaluation results of the colorectal cancer detection performance of test example 3 are shown, including (a) the distribution diagram of the comprehensive scores of colorectal cancer (positive) and normal samples (negative); and (b) the receiver operating characteristic curve (ROC curve).
[0065] Figure 8 The evaluation results of gastric cancer detection performance of test example 3 are shown, including (a) distribution diagram of comprehensive scores of gastric cancer (positive) and normal samples (negative); and (b) receiver operating characteristic curve (ROC curve).
[0066] Fig. 9 The evaluation results of the esophageal cancer detection performance of test example 3 are shown, including (a) the distribution diagram of the comprehensive scores of esophageal cancer (positive) and normal samples (negative); and (b) the receiver operating characteristic curve (ROC curve).
[0067] Fig.10 The evaluation results of liver cancer detection performance of test example 3 are shown, including (a) distribution diagram of comprehensive scores of liver cancer (positive) and normal samples (negative); and (b) receiver operating characteristic curve (ROC curve).
[0068] Fig.11 The evaluation results of the pancreatic cancer detection performance of Test Example 3 are shown, including (a) the distribution diagram of the comprehensive scores of pancreatic cancer (positive) and normal samples (negative); and (b) the receiver operating characteristic curve (ROC curve).
[0069] Fig.12 The evaluation results of lung cancer detection performance of test example 3 are shown, including (a) distribution diagram of comprehensive scores of lung cancer (positive) and normal samples (negative); and (b) receiver operating characteristic curve (ROC curve). DETAILED DESCRIPTION
[0070] The present invention is based on non-bisulfite technology and multi-gene qPCR detection technology. By optimizing the reaction conditions for nucleic acid extraction and purification of peripheral blood free DNA (cfDNA), the nucleic acid extraction rate is improved, and the occurrence of large fragment contamination during the extraction process is greatly reduced; by screening methylated immunoprecipitated 5-methylcytosine efficient antibodies and adjusting the methylated antigen-antibody reaction conditions, the enrichment and purification effect of methylated target nucleic acids is further improved, the methylated fragment recovery rate is increased, and non-specific enrichment reactions are effectively reduced by adding modified lambda DNA fragments and other means. Compared with traditional bisulfite treatment, the present invention achieves more efficient cfDNA extraction and methylation enrichment and purification, avoids excessive loss of trace signals, and protects the integrity of early signals of tumorigenesis.
[0071] Furthermore, by adding library adapters to peripheral blood free DNA before methylation treatment, and after A-terminal repair, the methylated fragments are enriched by optimized immunoprecipitation technology, and then the purified products are amplified indiscriminately. The multi-target gene probe primer pairs are designed using the non-CU conversion principle, so that the fluorescent quantitative qPCR instrument can achieve the effect of multi-gene simultaneous detection of methylation levels, and has high sensitivity, and the cost can be controlled to the level of hundreds of yuan. It avoids the high cost of high-throughput sequencing and has extremely high clinical popularity.
[0072] The qPCR-based peripheral blood free DNA multi-gene methylation detection system includes:
[0073] 1) cfDNA extraction unit: used to extract cfDNA from plasma samples. When the extracted cfDNA meets the following indicators, it enters the cfDNA methylation enrichment and purification unit:
[0074] The double-stranded DNA yield of the extracted product detected by Qubit nucleic acid concentration detector was no less than 0.5 ng per mL of plasma;
[0075] 2) cfDNA methylation enrichment and purification unit: used to pre-amplify cfDNA and enrich and purify methylated DNA using immunoprecipitation to obtain an indiscriminately amplified methylated DNA enriched library;
[0076] When the recovery rate of the methylated quality control product (a commercially synthesized methylated sequence that is not derived from any model species and is used as an internal standard) is not less than 65%, and the recovery rate of the unmethylated quality control product (a commercially synthesized unmethylated sequence that is not derived from any model species and is used as an internal standard) is not higher than 1%, enter the qPCR amplification unit;
[0077] The recovery rate calculation formula is: Recovery efficiency (%) = 2^(Ct 10%input -Ct 样本 -3.32)×100.
[0078] During the test, 10% of the sample was aspirated as the 10% input sample, and the remaining sample was processed later. The two were amplified together by qPCR. Ct10%input represents the ct value of the 10% input sample amplification; Ctsample represents the Ct value of the amplified sample.
[0079] 3) qPCR detection unit: used to amplify and detect methylated DNA; including:
[0080] I. Design primer and probe combinations for differentially methylated regions;
[0081] II. Perform qPCR reaction to obtain qPCR test results.
[0082] Preferably, each differentially methylated region covers no less than 4 CpG sites.
[0083] Preferably, the internal reference gene is TSH2B, and the Hg38 coordinate chromosome position is chr6:25726855-25727020; TSH2B is a human hypermethylated region, and is used to evaluate the overall level of methylated regions contained in the sample after MeDIP enrichment.
[0084] Preferably, the internal reference gene also includes GAPDH, which is a human hypomethylated region and is used to evaluate the level of non-specific enrichment of the sample after MeDIP. The Hg38 coordinate chromosome position is: chr12: 6534476-6534539.
[0085] The qPCR test results obtained by this system are applicable to a variety of analysis methods, thereby providing a data analysis basis for disease diagnosis and risk assessment. There is no restriction on the analysis method and analysis software, and those skilled in the art can choose according to actual conditions.
[0086] Preferably, the system further comprises:
[0087] 4) Algorithm analysis unit: used to analyze the qPCR test results, including: calculating ΔCT by subtracting the CT value of the reference gene from the CT value of the target gene; calculating the logistic score of each sample by a logistic regression model (LogisticRegression) based on the ΔCT value of a single gene or multiple genes, selecting an appropriate cut-off value (cut-off value) according to different logistic scores, and judging the sample as positive when the score is higher than the cut-off value, and judging the sample as negative when the score is lower than the cut-off value.
[0088] The calculation formula for the logical score of each gene is:
[0089] Logistic score=β0+β1*X1+β2*X2+β3*X3.....+βn*Xn
[0090] Gene score = e logistic score / (1+e logistic score )
[0091] Where β0 represents a constant, β1 represents the weight coefficient of each gene, and X represents each gene.
[0092] The above calculations and analyses can be performed using a variety of computational tools in commercial software.
[0093] The principle of this system is that the qPCR technology based on the existing bisulfite methylation analysis can only achieve the simultaneous detection of a limited number of methylated genes for a single ctDNA sample. The limiting factor is that the main problem of the current plasma free DNA extraction kit is the low extraction efficiency. Even the commercial kit with the best extraction effect abroad cannot meet the needs of qPCR for simultaneous detection of multiple genes. In addition, the morphology of the converted DNA obtained by the mainstream methylation treatment method (bisulfite) for the extracted free DNA is: mainly single-stranded, double-stranded mixed, fragment nicks, gap damage, and uracil state nucleotides. This process generally causes 90% of the DNA template to be lost, and a large amount of methylation information cannot be detected by subsequent processes. At the same time, during the base conversion treatment, there is an incomplete sequence conversion or excessive conversion, which produces artificial bias, and the subsequent PCR amplification will be further amplified, resulting in inaccurate signals. After the free DNA fragments, which are originally limited in number in the plasma sample, are treated with bisulfite, it is more difficult to detect the methylation level of multiple genes.
[0094] Therefore, in order to achieve the goal of qPCR to detect multiple (more than ten) genes at the same time, the entire system needs to be improved. First, the extraction effect of peripheral blood free DNA (cfDNA) must reach a double-stranded DNA yield of no less than 0.5ng per mL of plasma, that is, the efficiency of the extracted product must be more than twice that of the conventional extraction kit, and human bias must be minimized to ensure the quality of the extracted product, so that the obtained extracted product is more conducive to downstream enrichment, amplification, and detection procedures.
[0095] Secondly, based on the extraction products that meet the above standards, when the methylation fragment recovery rate reaches more than 65%, it can meet the needs of qPCR multi-gene detection. The recovery rate of the traditional bisulfite conversion method is less than 10%, which cannot meet this standard. Therefore, the system requires the extraction product to be amplified by immunoprecipitation to achieve the effect of efficient methylation enrichment. In addition, the sequence changes after traditional bisulfite treatment, while the gene sequence remains unchanged in the methylation immunoprecipitation enrichment method, so pre-amplification can be performed to indiscriminately expand the abundance of methylation signals for subsequent multi-gene detection.
[0096] This system sets corresponding standards for cfDNA extraction and methylation enrichment and purification, with the aim of avoiding excessive loss of trace signals, protecting the integrity of early signals of tumorigenesis, improving the sensitivity of methylation signals, and enhancing the sensitivity of target gene detection, ultimately meeting the needs of qPCR multi-gene detection.
[0097] More specifically, the specific operations of each unit in this system are as follows:
[0098] 1) In the cfDNA extraction unit, in order to achieve a double-stranded DNA yield of no less than 0.5 ng per mL of plasma, the present invention systematically adjusts and combines the lysate, magnetic beads, washing solution and other reagents used in the extraction process, as well as the reaction conditions, operating steps, etc.
[0099] In the process of extracting free DNA from peripheral blood, lysis buffer 1 (mainly composed of SDS component) is first used to denature the proteins in serum plasma, thereby improving the effect of the second digestion of the sample by lysis buffer 2 (mainly composed of guanidine isothiocyanate component), while also reducing the nonspecific adsorption of protein macromolecules to magnetic beads, which is beneficial to improving the yield and purity of nucleic acid.
[0100] In view of the problem that different anticoagulant blood collection tubes have different degrees of influence on the quality of plasma nucleic acid, the present invention compares different chelating agents and concentrations such as sodium tartrate, sodium gluconate and EDTA. Preferably, 0.05% to 0.2% sodium tartrate is added to the lysate 2 to achieve compatibility with different types of blood collection tubes.
[0101] Furthermore, 25% isopropanol was added to the lysis solution 2 to improve the stability of the nucleic acid fragments and reduce degradation. The salt environment for nucleic acid lysis was optimized by adjusting the concentration ratio of sodium chloride and potassium chloride.
[0102] Commonly used nucleic acid binding magnetic beads are mainly amino magnetic beads, carboxyl magnetic beads, silica magnetic beads and amino-silica magnetic beads, depending on the type of surface modification. In view of the fragmentation and trace characteristics of free DNA in human peripheral blood, amino-silica magnetic beads with a solid content of 1% to 5% are preferred because they can more stably and efficiently bind cfDNA, including methylated cfDNA, and have high adsorption efficiency.
[0103] An environment with appropriate concentrations of salt, anhydrous ethanol and isopropanol is conducive to promoting the adsorption of cfDNA onto magnetic beads, while an appropriate concentration of proteinase K can promote complete digestion of proteins.
[0104] The effect of washing solution 1 focuses on removing impurities such as protein, sugar and isopropanol. Washing solution 2 can further remove salt impurities.
[0105] By selecting the above reagents, optimizing their combination, and adjusting their concentration ratios, they work together during the extraction process, greatly improving the efficiency and quality of peripheral blood free DNA nucleic acid extraction.
[0106] The amount of each reagent used in the extraction process can be adaptively adjusted according to the amount of plasma and the proportion of plasma volume. Taking the extraction of cfDNA from 2mL plasma as an example, the specific method includes the following steps:
[0107] S11. Place the plasma in a centrifuge tube containing 100 μL to 150 μL of proteinase K, add 100 μL to 150 μL of lysis solution 1, mix well, react at 15-60°C for 10-60 minutes, for example, at 55°C for 30 minutes, to obtain a mixed solution.
[0108] The lysis solution 1 contains sodium dodecyl sulfate (SDS); preferably, the lysis solution 1 contains 0.05% to 1% sodium citrate dodecahydrate and 1% to 5% SDS.
[0109] In this embodiment, the components of the lysis solution 1 are 0.07% sodium citrate dodecahydrate and 4% SDS.
[0110] S12, add 4 mL to 8 mL of lysate 2 and 30 μL to 50 μL of magnetic beads to the mixed solution obtained in step 11, mix at room temperature (e.g., invert to mix), react for 10-60 minutes, e.g., 10 minutes; transfer to a magnetic rack after centrifugation, let stand for 2-10 minutes to adsorb the magnetic beads, and discard the solution.
[0111] Lysis solution 2 comprises 10% to 20% guanidine thiocyanate, 1% to 5% alkoxypolyethylene hydroxyethanol (NP40), 3% potassium chloride, 2% sodium chloride, 0.5% to 1% tris(hydroxymethyl)aminomethane, 0.05% to 0.2% sodium tartrate and 25% isopropanol; preferably, lysate 2 comprises 20% guanidine thiocyanate, 3% NP40, 3% potassium chloride, 2% sodium chloride, 2% to 10% sodium lauroyl aminoacid, 0.1% to 0.3% sodium dihydrogen phosphate, 0.7% tris(hydroxymethyl)aminomethane, 0.05% sodium tartrate and 25% isopropanol.
[0112] In this embodiment, the components of lysate 2 are 20% guanidine thiocyanate, 3% NP40, 3% potassium chloride, 2% sodium chloride, 4% sodium lauroyl amino acid, 0.1 sodium dihydrogen phosphate, 0.7% tris(hydroxymethyl)aminomethane, 0.05% sodium tartrate and 25% isopropanol.
[0113] Preferably, the magnetic beads are amino-siliconized magnetic beads with a solid content of 1% to 5%. In this embodiment, the magnetic beads are 2.5% (w / v) silica amino magnetic beads (Silica Magnetic Beads (-NH2)). The present invention does not limit the dilution concentration of the magnetic beads in the reaction system when used. Those skilled in the art can dilute the magnetic bead stock solution according to actual conditions, for example, dilute it to 0.003%-0.01% magnetic bead suspension.
[0114] S13, add 0.5mL-0.8mL washing solution 1, mix well (for example, invert and mix well), centrifuge, place on a magnetic stand for adsorption for 1-3 minutes, for example, 1 minute, and discard the solution. This step can be repeated 1-5 times according to actual needs.
[0115] The washing solution 1 contains 20% to 25% guanidine thiocyanate, 0.2% to 1% SDS and 30% to 50% anhydrous ethanol; preferably, the washing solution 1 contains 25% guanidine thiocyanate, 0.2% to 0.5% tris(hydroxymethyl)aminomethane, 1.5% to 5% potassium chloride, 0.5% SDS and 50% anhydrous ethanol.
[0116] In this embodiment, the components of the washing solution 1 are 25% guanidine thiocyanate, 0.3% tris(hydroxymethyl)aminomethane, 2% potassium chloride, 0.5% SDS and 50% anhydrous ethanol.
[0117] S14, add 0.5mL-0.8mL washing solution 2, mix well (e.g., vortex for 5 seconds), transfer to the magnetic stand for adsorption for 1 minute, and discard the solution. This step can be repeated 1-3 times according to actual needs.
[0118] The components of the washing liquid 2 are 0.1% to 0.8% of tris(hydroxymethyl)aminomethane, 0.5% to 1% of 4-(1,1,3,3-tetramethylbutyl)phenyl-polyethylene glycol, t-octylphenoxypolyethoxyethanol, polyethylene glycol tert-octylphenyl ether (Trinton X-100) and 70% to 80% of anhydrous ethanol.
[0119] In this embodiment, the components of the washing solution 2 are 0.3% tris(hydroxymethyl)aminomethane, 0.7% Trinton X-100, and 75% anhydrous ethanol.
[0120] S15. After centrifugation, aspirate all the residual liquid; air dry the magnetic beads for 2 to 5 minutes, and avoid over-drying.
[0121] S16. Add 50 μL to 100 μL of elution buffer 1 and oscillate at 37°C for 5 minutes to fully dissolve the DNA; transfer to a magnetic rack and adsorb for 1-3 minutes, transfer the supernatant containing cfDNA to a new centrifuge tube to obtain the cfDNA extraction product.
[0122] The eluent 1 contains 0.05% to 0.2% tris(hydroxymethyl)aminomethane.
[0123] In this embodiment, the eluent 1 is 0.1% tris(hydroxymethyl)aminomethane.
[0124] The concentration units of the components of the above-mentioned lysate 1-2, washing solution 1-2 and eluent 1 are mass percentages.
[0125] 2) cfDNA methylation enrichment and purification unit:
[0126] This unit uses a non-bisulfite conversion, non-enzymatic conversion, 5mC detection method for free DNA methylation enrichment and purification in human peripheral blood. This method uses antibodies to capture methylated DNA and uses the antibodies to immunoprecipitate methylated DNA. This method can separate specific DNA from the sample and requires the antibody to be coupled to a fixed matrix (such as magnetic beads) within the required time range to separate the DNA, including the following steps:
[0127] S21. Add Escherichia coli phage DNA (λDNA) to the sample to be tested as a DNA methylation protective agent, that is, obtain a sample with added λDNA by quantitatively adding methylated λDNA and non-methylated λDNA as protective agents for competitive binding.
[0128] The starting mass of cfDNA samples is generally not less than 0.5ng; the mass ratio of cfDNA to DNA methylation protectant is in the range of 1:10-1:40. The volume after mixing has little effect on the subsequent reaction, and technicians in this field can adjust the total volume of the sample mixture to which λDNA is added according to actual conditions.
[0129] For example, the configuration of the sample with added λDNA is as follows: the mass of the cfDNA sample starts at 0.5ng, the volume of the cfDNA sample is 42μL, the concentration of the DNA methylation protectant is 50ng / μL, the volume of the added DNA methylation protectant is 0.1-15μL, so that the mass ratio of cfDNA to DNA methylation protectant is in the range of 1:10-1:40, and water is added to make the total volume of the sample mixture with added λDNA reach the selected volume, for example, 55-60μL.
[0130] Preferably, in the sample to which λDNA is added, the concentration ratio of the cfDNA template to the DNA methylation protectant (λDNA) is 1:10-1:40.
[0131] Preferably, the concentration ratio of methylated λDNA:unmethylated λDNA is 1:1.
[0132] S22. Mix the immunoprecipitation buffer and the sample to which λDNA is added (for example, by gently pipetting and mixing), incubate at 90-95°C for 5-20 minutes, and then cool rapidly to obtain a mixed solution.
[0133] Preferably, during mixing, the volume ratio of the immunoprecipitation buffer and the sample to which λDNA is added is 33 μL:57 μL.
[0134] S23. Add the antibody and magnetic beads to the mixed solution obtained in step S22, and incubate at 2-8°C for 4-16 hours, for example, at 4°C for 8 hours.
[0135] Preferably, this step S23 also includes pre-treatment steps: a magnetic bead washing step and an antibody dilution step.
[0136] Washing step of magnetic beads: Pipette 2-6 μL of magnetic bead stock solution (10 mg / mL) and wash the magnetic beads with ten-fold diluted immunoprecipitation buffer, wash at least twice, and resuspend with 20 μL of ten-fold diluted immunoprecipitation buffer for the last time to obtain a magnetic bead suspension with a concentration of 1-3 mg / mL, preferably a 2.5 mg / mL magnetic bead suspension.
[0137] Antibody dilution step: dilute the 5-methylcytosine antibody with a stock concentration of 1 mg / mL by 10-100 times using a ten-fold diluted immunoprecipitation buffer to obtain a solution with an antibody concentration of 0.01-0.1 mg / mL, preferably 0.02-0.05 mg / mL.
[0138] Preferably, the antibody, magnetic beads, and the mixed solution obtained in step S22 are mixed in the following ratio: 1 μL antibody: 1 μL magnetic beads: 15 μL mixed solution obtained in step S2.
[0139] Preferably, the magnetic beads are 2.8 μm superparamagnetic microbeads with affinity-purified IgG covalently coupled to their surfaces. For example, Dynabeads TM M-280 goat anti-mouse IgG magnetic beads (Thermo Fisher Scientific (USA), catalog number: 11202D), DiaMag anti-mouse IgG coated magnetic beads (Diagenode (Belgium), catalog number: C03010022-220), IgGMagBeads Goat anti-Mouse (Yisun Biotechnology (Shanghai) Co., Ltd., catalog number: 47502ES03).
[0140] Preferably, the antibody is a 5-methylcytosine antibody (monoclonal antibody, MeDIP / CHIP grade), for example, mouse monoclonal antibody [33D3] to 5-methylcytosine (5-mC) (product name: Anti-5-methylcytosine (5-mC) antibody [33D3], Abcam (Shanghai) Trading Co., Ltd., catalog number: ab10805), 5-Methylcytosine (5-mC) Monoclonal Antibody [33D3] (Epigentek, catalog number: A-1014-010), 5-methylcytosine (5-mC) Antibody-clone 33D3 (Diagenode, catalog number: C15200003).
[0141] S24. After brief centrifugation, place on a pre-cooled magnetic rack and discard the supernatant; wash the magnetic beads with washing solution.
[0142] Preferably, at least two washing solutions (such as immunoprecipitation buffer, 1-4M NaCl solution, etc.) are used to wash the magnetic bead precipitate, and the washing is performed at least four times, and the residual liquid is discarded each time by centrifugation. More preferably, one of the washing solutions is: a ten-fold diluted immunoprecipitation buffer; the other washing solution is a ten-fold diluted immunoprecipitation buffer with a high sodium chloride salt concentration, and its components are 0.01-0.02M (mol / L) sodium phosphate solution (PH=7.0), 1-4M sodium chloride solution, 0.1%-0.5% Triton X-100; preferably, the components are 0.02M sodium phosphate solution, 2M sodium chloride solution, and 0.5% Triton X-100.
[0143] More preferably, two washing solutions with different salt ion concentrations are combined and gradient dilutions with different salt ion concentrations are performed to further reduce non-specific amplification. Specifically, the cells are first washed twice with a ten-fold diluted immunoprecipitation buffer with a low sodium chloride salt concentration, and then washed twice with a ten-fold diluted immunoprecipitation buffer with a high sodium chloride salt concentration.
[0144] In each of the above steps, the ten-fold diluted immunoprecipitation buffer comprises a 0.01-0.02M (mol / L) sodium phosphate solution (PH=7.0), a 0.1-0.2M sodium chloride solution, and 0.1%-0.5% Triton X-100; preferably, the components are 0.02M sodium phosphate solution, 0.2M sodium chloride solution, and 0.5% Triton X-100.
[0145] The operation method is to dilute the immunoprecipitation buffer tenfold. Those skilled in the art can perform the operation according to conventional procedures, for example, mixing the immunoprecipitation buffer with TE solution (10mM Tris-HCl 1mM EDTA PH=8.0) (Biyuntian, R0225) or nuclease-free water in a volume ratio of 1:9.
[0146] Ten-fold diluted immunoprecipitation means the immunoprecipitation buffer was diluted ten-fold.
[0147] S25. Elute the DNA with Elution Buffer 2 at 50-60°C / 15 min, 95-100°C / 15 min. For example, at 55°C / 15 min, 100°C / 15 min.
[0148] The present invention does not limit the eluent 2, and those skilled in the art can select a commercial product or prepare it by themselves according to their needs.
[0149] Preferably, the eluent 2 comprises 0.01-0.1M Tris-HCl, 0.01-0.1M EDTA, 0.001-0.1% SDS, 0.1-1mg / mL proteinase K. More preferably, the eluent 2 comprises 0.05M Tris-HCl, 0.01M EDTA, 0.001% SDS, 0.4mg / mL proteinase K.
[0150] The test data was analyzed and the recovery efficiency was used as the evaluation index. The formula is as follows:
[0151] Recovery efficiency (%) = 2^(Ct 10%input -Ct 样本 -3.32)×100.
[0152] During the test, 10% of the sample was aspirated as the 10% input sample, and the remaining sample was processed later. The two were amplified together by qPCR, and Ct 10%input Indicates the Ct value of 10% input sample amplification; Ct 样本 Indicates the Ct value of the amplified sample.
[0153] In this example, the enrichment of methylated DNA was completed according to the following steps:
[0154] S21. Add 50-200 ng of λDNA, for example, 120 ng of λDNA, to a cfDNA sample with a mass of 5 ng, wherein the mass ratio of methylated λDNA to unmethylated λDNA is 1: 1. In this embodiment, 0.1-15 μL of a DNA methylation protective agent with a concentration of 50 ng / μL is added to a sample to be tested with a mass of cfDNA of not less than 0.5 ng, so that the mass ratio of cfDNA to DNA methylation protective agent is in the range of 1:10-1:40, and the volume of the sample to which λDNA is added is supplemented to 57 μL.
[0155] S22. Mix 33 μL of immunoprecipitation buffer and 57 μL of sample with λDNA added, incubate at 95℃ for 10 min, and cool on ice for 15 min. Then take 7.5 μL of the reaction solution as input and store at 2-8℃. Take 75 μL of the remaining solution for subsequent experiments.
[0156] S23. Washing the magnetic beads: Pipette 2-6 μL of the magnetic bead stock solution (10 mg / mL) and wash the magnetic beads twice with ten-fold diluted immunoprecipitation buffer, and resuspend them for the last time with 20 μL of ten-fold diluted immunoprecipitation buffer to obtain a magnetic bead suspension with a concentration of 2.5-3 mg / mL.
[0157] Dilute the antibody: Dilute the 5-methylcytosine antibody with a stock concentration of 1 mg / mL by 10-100 times using ten-fold diluted immunoprecipitation buffer to obtain an antibody solution with a concentration of 0.03-0.05 mg / mL.
[0158] Add 5 μL of antibody solution and 5 μL of magnetic bead suspension to 75 μL of the mixture obtained in step S2, and incubate at 4°C with rotation for 4-16 hours.
[0159] S24. Add 100 μL of ten-fold diluted immunoprecipitation buffer in an ice bath, invert to resuspend the magnetic beads, rotate and incubate at 4°C for 5 min (40 rpm), centrifuge immediately after the end, place on a pre-cooled magnetic stand, wait for 1 min, and discard the supernatant. Repeat the same steps at least once.
[0160] Add 100 μL of ten-fold diluted immunoprecipitation buffer with high sodium chloride concentration in an ice bath, invert and resuspend the magnetic beads, rotate and incubate at 4°C for 5 minutes (40 rpm), centrifuge immediately after the end, place on a pre-cooled magnetic stand, wait for 1 minute, and discard the supernatant. Repeat the same steps at least once.
[0161] The components of the ten-fold dilution immunoprecipitation buffer with high sodium chloride salt concentration are: 0.02M sodium phosphate solution, 2M sodium chloride solution, 0.5% Triton X-100.
[0162] S25. Elute DNA with elution buffer 2 at 55°C / 15 min and 100°C / 15 min.
[0163] Elution buffer 2 includes 0.01-0.1 M Tris-HCl, 0.01-0.1 M EDTA, 0.001-0.1% SDS, and 0.1-1 mg / mL proteinase K.
[0164] 3) In the qPCR detection unit: This system can detect nearly 100 gene loci simultaneously.
[0165] When the number of genes to be tested is large, for example, more than ten genes, the indiscriminately amplified methylated DNA enriched library obtained by the cfDNA methylation enrichment purification unit is pre-amplified. Those skilled in the art can choose to use a kit constructed by a commercial company or a self-developed library according to actual conditions. For example, Rapid Plus DNA Lib Prep Kit for illumina (Cat. No. RK20208, ABclonal) or VAHTS Universal Pro DNA LibraryPrep Kit for illuminaVazyme (Cat. No. ND608-02, Norwegian) and other similar kits perform end repair, add "A" tails, and connect to Adapters connectors. The above-mentioned products with added adapters were pre-amplified using KAPA HiFi Hotstart Ready mix and Library Amplification Primer Mix or Vazyme PCR Primer Mix 3forIllumina and VAHTS HiFi Amplification Mix; after amplification, VAHTS DNA Clean Beads (Cat. No. N411-03, Vazyme) were used to purify the products.
[0166] 3.1 Primer and probe design
[0167] Primer probe pairs suitable for fluorescence quantitative PCR detection can be designed based on cancer-specific differentially methylated regions screened out by high-throughput sequencing analysis or differentially methylated genes reported in publicly published data literature.
[0168] In order to achieve the purpose of simultaneously detecting multiple genes, it is preferred that the differentially methylated region contains at least 4 CpG sites to enhance the specific recognition of the primers to the methylated region and increase the sensitivity and specificity. Those skilled in the art can select different differentially methylated regions according to actual conditions and design corresponding primer-probe combinations.
[0169] This embodiment designs primer probe combinations for 16 gene loci related to colorectal cancer (SALL1, ITGA4, Septin9-1), gastric cancer (OLIG2, RNF180, Septin9-2), esophageal cancer (CDO1, SHOX2, PAX1-2), liver cancer (IRF4, C1QL3), pancreatic cancer (PAX1-1, Septin9-3), and lung cancer (EMX1, BARX1, ZNF781) to simultaneously detect methylation levels. The above 16 gene loci are all cancer-specific correlation combinations after the inventors analyzed the methylation profiles of related cancer and non-cancer clinical samples through tumor methylation high-throughput sequencing.
[0170] The specific primer and probe sequences are shown in Table 1.
[0171] Table 1
[0172]
[0173] 3.2 Those skilled in the art can design different qPCR reaction systems and reaction procedures according to actual conditions.
[0174] In this embodiment, the target gene qPCR reaction system is shown in Table 2.
[0175] Table 2
[0176] Reagent components System (μL) Enzyme reaction solution 12.5 Upstream primer, 10 μM 0.5 Downstream primer, 10 μM 0.5 Probe, 10 μM 0.25 stencil 2 Hydration 9.25 Total 25
[0177] The qPCR reaction procedure is shown in Table 3.
[0178] Table 3
[0179]
[0180] After the reaction is completed, the qPCR test results are obtained.
[0181] 4) In the algorithm analysis unit, the offline data is analyzed using a logistic regression equation. Specifically, ΔCT is calculated by subtracting the CT value of the reference gene from the CT value of the target gene. The coefficient of each gene is then calculated using the logistic regression equation. Finally, the logic score of each gene is calculated using the following formula:
[0182] Logistic score=β0+β1*X1+β2*X2+β3*X3+β4*X4+β5*X5+.....+β n *X n
[0183] Comprehensive score = e logistic score / (1+e logistic score )×1000
[0184] Select an appropriate cut-off value as a judgment.
[0185] Where β0 represents a constant, β1 represents the weight coefficient of each gene, and X represents each gene.
[0186] The above calculations and analyses can be completed using a variety of computing tools in commercial software, such as SPSS Statistics v27.0.1.
[0187] Test Example 1 cfDNA Extraction
[0188] The 16 plasma samples were extracted according to the peripheral blood free DNA extraction method in the cfDNA extraction unit to obtain extraction products, and according to the instructions of the commercial reagent VAHTS Free-Circulating DNA Maxi Kit (NWZ reagent) to obtain extraction products.
[0189] The components of NWZ reagent include Proteinase K, VAHTS Particles G, Buffer L / B, Buffer WA, Buffer WB and Elution Buffer. Compared with this method, this reagent only has one lysis buffer Buffer L / B. When used, the lysis buffer Buffer L / B, magnetic beads VAHTS Particles G, proteinase K and sample are directly mixed together to complete the lysis and free DNA adsorption process. This method includes lysis buffer 1 and lysis buffer 2. Proteinase K and lysis buffer 1 are used to perform preliminary lysis on the sample, and then lysis buffer 2 and magnetic beads are used to complete the complete lysis of the sample and the adsorption of free DNA.
[0190] The difference in Ct values when using β-actin gene detection reflects the content of nucleic acid template; Qubit4.0 was used to quantitatively determine the double-stranded DNA concentration of the extracted product, and the results are shown in Table 4.
[0191] Table 4
[0192]
[0193]
[0194] The Ct values and concentration test results of samples 1-16 were summarized, and ΔCt and concentration ratio were calculated for the same sample, ΔCt = Ct value obtained by the method of Example 1 - Ct value obtained by the NWZ reagent method, concentration ratio = concentration obtained by the method of Example 1 / concentration obtained by the NWZ reagent method. The results showed that the Ct value of the product obtained by the method provided by the present invention was increased by 0.65 to 1.56, with an average increase of 1.06, and the concentration of the product obtained was 2.14 to 4.07 times that of the NWZ method, with an average of 2.65 times.
[0195] Capillary electrophoresis was performed using the Qsep100 fully automatic nucleic acid and protein analyzer to analyze the fragment size and distribution of the extracted products.
[0196] The results are as follows Figure 2 As shown, the extraction method of Example 1 also has a good extraction effect for extremely small amounts of nucleic acids in plasma ( Figure 2 Left); Under the same sample size, commercial kits are often unable to detect the main peak of cfDNA ( Figure 2 right).
[0197] The results are as follows Figure 3 As shown, the extraction method of Example 1 was used to obtain the main peak of the cfDNA extraction product at 160-175 bp ( Figure 3 Left), while the main peak of cfDNA extracted by commercial kit is 175-190bp ( Figure 3 Right), indicating that the quality of cfDNA extracted by the method provided by the present invention is better and closer to the reference value of plasma free DNA fragment length of 167bp.
[0198] The results are as follows Figure 4 As shown, by using the extraction method of Example 1, the cfDNA extraction product obtained has less large fragment contamination ( Figure 4 Left), compared with commercial kits, the error caused by operation is smaller.
[0199] Test Example 2cfDNA Methylation Enrichment
[0200] During the purification process of the cfDNA methylation enrichment purification unit, the following conditions were changed without changing the steps:
[0201] Control group: 1) No λDNA was added; 2) The concentrations of the components of the methylation immunoprecipitation buffer were: 0.15M sodium phosphate, 1.5M sodium chloride, and 3% Triton X-100; 3) The washing process was washed 3 times with a ten-fold dilution of the immunoprecipitation buffer with a low sodium chloride salt concentration.
[0202] This system: 1) Add 120ng modified λDNA (methylated λDNA: unmethylated λDNA=1:1) as a protective agent for methylated genes, 2) The concentrations of the components of the methylation immunoprecipitation buffer are: 0.2M sodium phosphate concentration, 2M sodium chloride concentration, and 5% Triton X-100 concentration; 3) Washing process: First wash twice with a ten-fold diluted immunoprecipitation buffer with a low sodium chloride salt concentration, and then wash twice with an immunoprecipitate with a high sodium chloride salt concentration.
[0203] The results are as follows Figure 5 As shown, the average methylation gene binding efficiency of the control group was 43.8%, and the average methylation gene binding efficiency of this system was 66.74%.
[0204] Test Example 3
[0205] Without changing the system, only the components of the immunoprecipitation buffer in the cfDNA methylation enrichment purification unit were adjusted, and the Ct values of the TSH2B gene and GAPDH gene were used to observe the effect.
[0206] The different components of the immunoprecipitation buffer were adjusted to obtain the different combinations shown in Table 5.
[0207] Table 5
[0208]
[0209]
[0210] The corresponding ten-fold diluted immunoprecipitation fraction concentrations are shown in Table 6.
[0211] Table 6
[0212]
[0213] The test results are shown in Table 7, where P1 and P2 are colorectal cancer positive samples, N1 and N2 are normal negative samples, PC and NC are positive quality control (commercial human fully methylated genomic DNA) and negative quality control (commercial human non-methylated genomic DNA), respectively.
[0214] Table 7
[0215]
[0216] The dosage of sodium phosphate was optimized through combination 1, combination 2, and combination 3, the dosage of sodium chloride was optimized through combination 1, combination 4, and combination 5, the dosage of Trition X-100 was optimized through combination 1, combination 6, and combination 7, and finally the dosage of each component was optimized through combination 8 and combination 9. In the test results, the smaller the Ct value of TSH2B, the more methylated fragments were enriched, and the better the result, and the larger the Ct value of GAPDH, the less nonspecific enrichment, and the better the result. It can be seen that the enrichment effect of all combinations meets the requirements; among them, combination 9 has the least nonspecific detection and a high total enrichment rate. Combination 9, i.e., a combination with a sodium phosphate concentration of 0.2M, a sodium chloride concentration of 2M, and a Triton X-100 concentration of 5%, is preferred.
[0217] Test case 4 qPCR detection and algorithm analysis
[0218] In the fluorescence PCR amplification, all 16 gene loci related to colorectal cancer (SALL1, ITGA4, Septin9-1), gastric cancer (OLIG2, RNF180, Septin9-2), esophageal cancer (CDO1, SHOX2, PAX1-2), liver cancer (IRF4, C1QL3), pancreatic cancer (PAX1-1, Septin9-3), and lung cancer (EMX1, BARX1, ZNF781) were single-gene amplification, that is, one reaction well amplified one gene methylation region.
[0219] Among them, Septin9-1, Septin9-2, and Septin9-3 are different regions of the same gene that are most relevant to the corresponding cancer types.
[0220] 300 cancer samples were selected, including 71 cases of colorectal cancer, 57 cases of gastric cancer, 29 cases of esophageal cancer, 56 cases of liver cancer, 17 cases of pancreatic cancer, 70 cases of lung cancer, and 124 clinical samples of normal health and benign diseases, totaling 424 clinical samples. 5-10 mL of peripheral blood was collected for each sample and analyzed using this system. The methylated enriched product was used as a template for nucleic acid amplification, and 16 different gene methylation regions were amplified in 16 reaction wells. An optional scheme is that in the same reaction well, after the multi-gene amplification non-interference test, 1 to 4 fluorescence channels can be selected for detection according to the number of multiple fluorescence channels for multiple gene amplification. In this embodiment, single gene amplification is performed, that is, one gene is amplified in one reaction well.
[0221] The experimental process is shown in Figure 6 .
[0222] According to the logic formula, the gene combination was analyzed and found that: SALL1, ITGA4, Septin9-1 gene loci had methylation differences after algorithm analysis, which were related to colorectal cancer; OLIG2, RNF180, Septin9-2 gene loci had methylation differences after algorithm analysis, which were related to gastric cancer; CDO1, SHOX2, PAX1-2 gene loci had methylation differences after algorithm analysis, which were related to esophageal cancer; IRF4, C1QL3 gene loci had methylation differences after algorithm analysis, which were related to liver cancer; PAX1-1, Septin9-3 gene loci had methylation differences after algorithm analysis, which were related to pancreatic cancer; EMX1, BARX1, ZNF781 gene loci had methylation differences after algorithm analysis, which were related to lung cancer; The optimal combination and the corresponding cancer were selected for sensitivity and specificity analysis. When analyzing the performance of a single cancer type, only the corresponding cancer type samples were analyzed. For example, when analyzing the performance of colorectal cancer, only the colorectal cancer samples among the 300 cancer clinical samples were analyzed.
[0223] The specific statistics are as follows:
[0224] 195 colorectal clinical samples were selected, including 71 cases of colorectal cancer and 124 normal negative cases. The methylation level detection data of SALL1, ITGA4, and Septin9-1 were obtained through this system, and the detection performance was analyzed using the logistic regression formula and ROC curve. Colorectal cancer: logistic score = 13.84-2.38×△Ct(SALL1)-0.20×△Ct(ITGA4)-3.44×△Ct(Septin9-1)
[0225] Comprehensive score = e logistic score / (1+e logistic score )×1000
[0226] The cut-off value was 430.23 after calculation according to the logistic regression formula, and the area under the curve AUC was 0.94, with a sensitivity of 88.7% and a specificity of 93.5% ( Figure 7 ).
[0227] A total of 181 stomach-related clinical samples were selected, including 57 gastric cancer-positive samples and 124 normal-negative samples. They were processed by the detection process of this system, and the detection performance was analyzed by the logistic regression formula and ROC curve combined with the methylation levels of OLIG2, RNF180, and Septin9-2.
[0228] Gastric cancer: logistic score = -0.363-0.71×△Ct(OLIG2)-0.141×△Ct(RNF180)-1.679×△Ct(Septin9-2)
[0229] Comprehensive score = e logistic score / (1+e logistic score )*1000
[0230] The cut-off value was 371.41 after calculation according to the logistic regression formula, and the area under the curve AUC = 0.955, with a sensitivity of 87.7% and a specificity of 92.7%. Figure 8 )
[0231] A total of 153 esophageal-related clinical samples were selected, including 29 positive cases of esophageal cancer and 124 normal negative cases. They were processed by the detection process of this system, and the detection performance was analyzed by the logistic regression formula and ROC curve combined with the methylation levels of CDO1, SHOX2, and PAX1-2.
[0232] Esophageal cancer: logistic score = 1.237-0.666×△Ct(CDO1)-0.148×△Ct(SHOX2)-2.542×△Ct(PAX1-2)
[0233] Comprehensive score = e logistic score / (1+e logistic score )*1000
[0234] After calculation according to the logistic regression formula, the cut-off value was 536.62, and the area under the curve AUC = 0.943, with a sensitivity of 82.8% and a specificity of 91.9%. Fig. 9 )
[0235] A total of 180 liver-related clinical samples were selected, including 56 liver cancer-positive samples and 124 normal-negative samples. They were processed by the detection process of this system, and the detection performance was analyzed by the logistic regression formula and ROC curve combined with the methylation levels of IRF4 and C1QL3.
[0236] Liver cancer: logistic score = 4.748-0.096×△Ct(IRF4)-1.328×△Ct(C1QL3)
[0237] Comprehensive score = e logistic score / (1+e logistic score )*1000
[0238] After calculation according to the logistic regression formula, the cut-off value was 435.8, the area under the curve AUC = 0.932, the performance was 83.9% sensitivity, and 91.1% specificity. Fig.10 )
[0239] A total of 141 pancreatic-related clinical samples were selected, including 17 pancreatic cancer-positive samples and 124 normal-negative samples. They were processed by the detection process of this system, and the detection performance was analyzed by the logistic regression formula and ROC curve combined with the methylation levels of PAX1-1 and Septin9-3.
[0240] Pancreatic cancer: logistic score = 1.259-2.185×△Ct(PAX1-1)-0.357×△Ct(Septin9-3)
[0241] Comprehensive score = e logistic score / (1+e logistic score )*1000
[0242] After calculation according to the logistic regression formula, the cut-off value was 446.40, the area under the curve AUC = 0.917, and the performance of pancreatic cancer was 82.4% sensitive and 87.1% specific. ( Fig.11 )
[0243] A total of 194 lung-related clinical samples were selected, including 70 lung cancer-positive samples and 124 normal-negative samples. They were processed by the detection process of this system, and the detection performance was analyzed by the logistic regression formula and ROC curve combined with the methylation levels of EMX1, BARX1, and ZNF781.
[0244] Lung cancer: logistic score = 0.495-0.598×△Ct(EMX1)-0.023×△Ct(BARX1)-2.096△Ct(ZNF781)
[0245] Comprehensive score = e logistic score / (1+e logistic score )*1000
[0246] After calculation according to the logistic regression formula, the cut-off value was 430.49, the area under the curve AUC = 0.93, and the lung cancer performance was 81.4% sensitive and 90.3% specific. Fig.12 )
[0247] The traditional extraction and bisulfite treatment methods have low cfDNA extraction and recovery efficiency and large losses during the intense methylation treatment process, which seriously reduces the methylation signal. Therefore, the current amplification is mostly 6 methylation regions (3 qPCR reaction wells). In the patent of this invention, the qPCR-based peripheral blood free DNA multi-gene methylation detection system improves the recovery efficiency by 2.6 times and the methylation enrichment efficiency by 10 to 30 times during the cfDNA extraction process. The signal richness of cfDNA methylation of early tumor signals is increased by 26 to 78 times compared with the traditional processing and purification system. The pre-amplification system can continue to amplify trace signals without offset, improve signal strength, and ensure that the input amount of nucleic acid template meets the needs of fluorescent PCR amplification analysis.
[0248] The methylation detection system in the present invention breaks through the systemic limitations of traditional methods and realizes the simultaneous detection of multiple genes in one tube of blood. The early screening of the six most common cancers has achieved the optimal combined simultaneous detection of genes through the amplification of 16 reaction wells, and has shown good performance. An optional scheme is that in the same reaction well, after the non-interference test of multi-gene amplification, 1 to 4 fluorescent channels can be selected for detection for multiple gene amplification according to the number of multiple fluorescent channels. In other words, the methylation detection system in the present invention can expand the detection of more cancer types and genes through multiplex qPCR, and can realize the simultaneous detection of more than ten cancer types and nearly a hundred gene loci.
[0249] The above specific implementations do not constitute a limitation on the protection scope of the present invention. It should be understood by those skilled in the art that various modifications, combinations, sub-combinations and substitutions can be made according to design requirements and other factors. Any modification, equivalent substitution and improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. qPCR-based peripheral blood free DNA multi-gene methylation detection system, including: 1) cfDNA extraction unit: used to extract cfDNA from plasma samples. When the double-stranded DNA yield of the extracted cfDNA product is not less than 0.5 ng per mL of plasma, it enters the cfDNA methylation enrichment and purification unit: 2) cfDNA methylation enrichment and purification unit: used to pre-amplify cfDNA and enrich and purify methylated DNA using immunoprecipitation to obtain an indiscriminately amplified methylated DNA enriched library; When the recovery rate of the methylated quality control product is not less than 65% and the recovery rate of the non-methylated quality control product is not higher than 1%, enter the qPCR amplification unit; 3) qPCR detection unit: used to detect methylated DNA and obtain qPCR detection results.
2. The qPCR-based peripheral blood free DNA multi-gene methylation detection system according to claim 1, characterized in that: In the cfDNA extraction unit, extracting cfDNA from plasma samples includes the following steps: S11. Place 2 mL of plasma into a centrifuge tube containing 100 μL to 150 μL of proteinase K, add 100 μL to 150 μL of lysis solution 1, mix well, and react at 15-60° C. for 10-60 minutes to obtain a mixed solution; S12. Add 4 mL to 8 mL of lysate 2 and 30 μL to 50 μL of magnetic beads to the mixed solution obtained in S11, mix well at room temperature, and react for 10 to 60 minutes; transfer to a magnetic rack after centrifugation, adsorb the magnetic beads, and discard the solution; S13. Add 0.5 mL to 0.8 mL of washing solution 1, mix well, centrifuge, place on a magnetic stand for adsorption, and discard the solution; S14. Add 0.5 mL to 0.8 mL of washing solution 2, mix well, transfer to a magnetic stand for adsorption, and discard the solution; S15. After centrifugation, remove all residual liquid; dry the magnetic beads in air for 2 to 5 minutes; S16. Add 50 μL to 100 μL of elution buffer 1, dissolve the DNA and transfer it to a magnetic rack for adsorption, transfer the supernatant containing cfDNA to a new centrifuge tube to obtain a cfDNA extraction product; Lysis buffer 1 contains 0.05% to 1% sodium citrate dodecahydrate and 1% to 5% SDS; Lysis solution 2 contains 10% to 20% guanidine thiocyanate, 1% to 5% NP40, 3% potassium chloride, 2% sodium chloride, 0.1% to 0.3% sodium dihydrogen phosphate, 0.5% to 1% tris(hydroxymethyl)aminomethane, 0.05% to 0.2% sodium tartrate and 25% isopropanol; The washing solution 1 comprises 20% to 25% guanidine thiocyanate, 0.2% to 1% SDS, and 30% to 50% anhydrous ethanol; Washing liquid 2 contains 0.1% to 0.8% tris(hydroxymethyl)aminomethane, 0.5% to 1% TrintonX-100, and 70% to 80% anhydrous ethanol; The eluent 1 contains 0.05% to 0.2% of tris(hydroxymethyl)aminomethane.
3. The qPCR-based peripheral blood free DNA multi-gene methylation detection system according to claim 2, characterized in that: Lysis buffer 1 consisted of 0.07% sodium citrate dodecahydrate and 4% SDS; Lysis solution 2 consists of 20% guanidine thiocyanate, 3% NP40, 3% potassium chloride, 2% sodium chloride, 4% sodium lauroyl amino acid, 0.1% sodium dihydrogen phosphate, 0.7% tris(hydroxymethyl)aminomethane, 0.05% sodium tartrate and 25% isopropanol; The washing liquid 1 further comprises 0.2% to 0.5% of tris(hydroxymethyl)aminomethane and 1.5% to 5% of potassium chloride; In the cfDNA extraction unit, the magnetic beads are amino-siliconized magnetic beads.
4. The qPCR-based peripheral blood free DNA multi-gene methylation detection system according to claim 1, characterized in that: In the cfDNA methylation enrichment and purification unit, a method for enriching methylated fragments in human peripheral blood free DNA comprises the following steps: S21. adding λDNA as a DNA methylation protective agent to the sample to be tested to obtain a sample to which λDNA is added; S22. Mix the immunoprecipitation buffer and the sample with added λDNA, incubate at 90-95°C for 5-20 minutes, and then cool rapidly to obtain a mixed solution; S23. Add the antibody and magnetic beads to the mixture obtained in step S22 and incubate at 2-8°C for 4-16 hours; S24. After instant centrifugation, place on a pre-cooled magnetic rack and discard the supernatant; wash the magnetic beads with washing solution; S25. Elute the DNA with elution buffer at 50-60°C / 15min, 95-100°C / 15min; In step S21, in the DNA methylation protective agent, the mass ratio of methylated λDNA to unmethylated λDNA is 1:1; In the samples with added λDNA, the concentration ratio of cfDNA to DNA methylation protectant is 1:10-1:40, and the concentration of cfDNA is not less than 0.01 ng / μL.
5. The qPCR-based peripheral blood free DNA multi-gene methylation detection system according to claim 4, characterized in that: In step S22, during mixing, the volume ratio of the immunoprecipitation buffer and the sample with added λDNA is (30-35) μL:(55-60) μL; Step S23 also includes a magnetic bead washing step and an antibody dilution step: Washing step of magnetic beads: take 2-6 μL of 10 mg / mL magnetic bead stock solution and wash the magnetic beads with ten-fold diluted immunoprecipitation buffer, wash at least twice, and resuspend with 20 μL of ten-fold diluted immunoprecipitation buffer for the last time to obtain a magnetic bead suspension with a concentration of 1-3 mg / mL; Antibody dilution step: dilute the 5-methylcytosine antibody at a concentration of 1 mg / mL by 10-100 times using a ten-fold diluted immunoprecipitation buffer to obtain a solution with an antibody concentration of 0.01-0.1 mg / mL; The antibody, magnetic beads, and the mixed solution obtained in step S2 are mixed in the following volume ratio: 1:1:(15-20).
6. The qPCR-based peripheral blood free DNA multi-gene methylation detection system according to claim 4, characterized in that: The immunoprecipitation buffer includes 0.1-0.2 M sodium phosphate solution, 1-2 M sodium chloride solution, and 1%-5% Triton X-100; In step S24, the washing solution includes a ten-fold diluted immunoprecipitation buffer and an immunoprecipitation buffer with a high sodium chloride salt concentration; the immunoprecipitation buffer with a high sodium chloride salt concentration comprises a 0.01-0.02M sodium phosphate solution, a 1-4M sodium chloride solution, and 0.1%-0.5% Triton X-100; In step S25, the eluent 2 includes 0.01-0.1 M Tris-HCl, 0.01-0.1 M EDTA, 0.001-0.1% SDS, and 0.1-1 mg / mL proteinase K.
7. The qPCR-based peripheral blood free DNA multi-gene methylation detection system according to claim 4, characterized in that: In the cfDNA methylation enrichment and purification unit, the magnetic beads are IgG magnetic beads; the antibody is 5-methylcytosine antibody.
8. The qPCR-based peripheral blood free DNA multi-gene methylation detection system according to claim 1, characterized in that: In the qPCR detection unit, primers and probes are designed for target-specific differential methylation regions, and the differential methylation regions cover no less than 4 CpG sites.
9. The qPCR-based peripheral blood free DNA multi-gene methylation detection system according to claim 1, characterized in that: In the qPCR detection unit, TSH2B was used as the internal reference gene in the qPCR reaction.
10. The qPCR-based peripheral blood free DNA multi-gene methylation detection system according to claim 9, characterized in that: The internal reference gene is TSH2B, and the chromosome position of Hg38 coordinates is: chr6:25726855-25727020.
11. The qPCR-based peripheral blood free DNA multi-gene methylation detection system according to claim 9 or 10, characterized in that: The internal reference gene also includes GAPDH, and the chromosome position of Hg38 coordinates is: chr12: 6534476-6534539.
12. The qPCR-based peripheral blood free DNA multi-gene methylation detection system according to claim 1, characterized in that: Also includes: 4) Algorithm analysis unit: used to analyze the qPCR test results, including: calculating ΔCT by subtracting the CT value of the reference gene from the CT value of the target gene; Combining the ΔCT values of a single gene or multiple genes, the logical score of each sample is calculated through a logistic regression model. Appropriate cutoff values are selected according to different logical scores. When the sample score is higher than the cutoff value, it is judged as positive, and when the sample score is lower than the cutoff value, it is judged as negative.
13. A kit for extracting and enriching methylated fragments in free DNA from human peripheral blood, comprising: The lysate 1, lysate 2, washing solution 1, washing solution 2 and eluent 1 described in claim 2 or 3, and the immunoprecipitation buffer, the ten-fold diluted immunoprecipitation buffer with a high sodium chloride salt concentration and the eluent 2 described in claim 4.
Citation Information
Cited By
Gene marker combination for diagnosing or predicting colorectal cancer and application thereof
CN119876391A
Methylation marker combination for colorectal cancer diagnosis or prediction, application, kit and computer readable storage medium
CN120624646A
Methylation marker combination for diagnosis or prediction of colorectal cancer and application, kit and computer readable storage medium
CN120624646B
Methylation marker combination for gastric cancer diagnosis or prediction, application, kit and computer readable storage medium
CN120648798A
Qpcr-based multi-gene methylation detection system for peripheral blood free DNA
WO2026081629A1
